Introduction p27 Kip1, a CIP/KIP member, encodes a CKI (cyclindependent kinase inhibitor) that causes G1 arrest by inhibiting the activities of G1 cyclin-CDK (Polyak et al., 1994) . Reduced expression of p27 is frequently detected in human cancers, and has been shown to correlate with cancer development and poor survival, thus appearing as an important marker of cancer progression (Clurman and Porter, 1998) . In addition, p27 is de®ned as a new class of tumor suppressor and is haplo-insucient in tumor suppression (Fero et al., 1998) . The HER2/neu oncogene (also named as c-erbB-2) encodes a growth receptor tyrosine kinase, and ampli®cation/overexpression of the human HER2/neu gene are frequently found in human cancers, including breast, ovarian, lung, gastric, and oral cancers (Hung et al., 1995; Slamon et al., 1989) . Also, HER2/neu overexpression correlates with a shorter survival rate in cancer patients (Slamon et al., 1987) . We previously demonstrated that HER2/neu activity speci®cally causes the decrease of p27 protein level by inducing the mislocation of p27 in the cytoplasm for enhanced ubiquitin-mediated degradation , thus presenting a potential point for therapeutic intervention in HER2/neu-associated cancers. Here, we examined the eectiveness of using p27 as a therapeutic agent for HER2/neu-overexpressing cancer under a gene expression system regulated by tet (Gossen and Bujard, 1992) . We demonstrated that the expression of p27 can inhibit HER2/neu-mediated cell proliferation, anchorage-independent growth, and cell transformation. Furthermore, we showed that p27 expression reduces tumorigenicity of HER2/neu-overexpressing cells in nude mice. These results indicate that approaches for modulating p27 activity may be useful for intervention in HER2/neu-overexpressing cancers.
Results

Overexpression of p27 inhibits cell growth and transformation mediated by HER2/neu-overexpression
To investigate the growth inhibitory eect of p27 on HER2/neu-activated cell growth, we performed a CDK2-associated Histone H1 kinase assay and a BrdU incorporation assay by cotransfecting HER2/neu with increasing amounts of p27 into mink lung epithelial cell R1B/L17. The phosphorylated Histone H1 was quantitated using a phosphoimager. A dramatic reduction of HER2/neu-activated CDK2 kinase activity was seen in cells transfected with increasing amounts of p27 as compared with the HER2/neu single-transfection control cells, whereas cotransfection with increasing amounts of empty vector (CMV) has no eect on HER2/neu-activated CDK2 kinase activity ( Figure 1A , B). Furthermore, p27 inhibited HER2/neu-mediated incorporation of BrdU ( Figure 1C ). Cotransfection of HER2/neu with p27 causes at least a 50% reduction in BrdU positive cells as compared with the HER2/neu single-transfection control cells ( Figure 1C,D) . To examine the inhibitory eect of p27 on the transformation phenotype of HER2/neu-overexpressing cells, the microfocus formation assay (Reardon and Hung, 1993) was used to analyse the capacity of p27 to inhibit the transformation of HER2/neu-transfected cells. We compared the numbers of microfoci formed in the experimental and control groups and found that increasing the expression of p27 can reduce the number of foci by more than 70% as compared with the HER2/neu single-transfection control cells ( Figure 1E ). The data indicate that ectopic expression of p27 can inhibit the mitogenic growth mediated by HER2/neu.
Tet-regulated p27 blocks G1 progression and the cell growth of HER2/neu-overexpressing cells
To further characterize the biological eects of p27 expression on HER2/neu-overexpressing cells, we employed a tet-inducible system (Gossen and Bujard, 1992) .
HER2/neu-overexpressing NIH3T3 cells (NIH3T3/HER2 or 10-1 cells) were used to stably express tTA (Transcriptional activator) by transfecting with pUHD15-1 (neo) vector (Gossen and Bujard, 1992) . Clones were further transfected with pUHC13-3 (tetO/HCMVIE-luciferase) (Gossen and Bujard, 1992) in the presence or absence of tet to examine the capacity of tet-o induction (Figure 2A ). F11 clone (NIH3/HER2/tTA) can activate luciferase activity in the absence of tet compared with the presence of tet (Figure 2A) , and it was further selected for further transfection with Flag-tagged p27 cloned in Figure 1 Inhibition of HER2/neu-activated CDK2 activity, BrdU incorporation, and transformation activity by p27. (A) Inhibition of HER2/neu-activated CDK2 kinase activity. R1B/L17 cells were co-transfected with HER2/neu and increasing amounts of p27 or empty vector (CMV). CDK2 was immunoprecipitated and CDK2-associated Histone H1 kinase activity was measured using Histone H1 as a substrate (HH1). (B) Comparison of CDK2 kinase activity. Experiment was performed as described in (A). The signal associated with phosphorylated Histone H1 bands was quantitated using a Phosphoimager, and the results are plotted as percentages relative to samples that received only HER2/neu. (C) BrdU incorporation. R1B/L17 cells were co-transfected with p27 and HER2/neu. Cells were labeled with BrdU 48 h post-transfection. Empty vector transfection (CMV) was used as a control. Cells were ®xed and analysed for immuno¯uorescence using monoclonal anti-BrdU antibody followed by FITC-conjugated anti-mouse immunoglobulin (a, b and c). Nuclei were visualized by DAPI staining of DNA (d, e and f). Combined FITC and DAPI staining is also shown (g, h and i). (D) Percentage of BrdU positive cells. Cells were labeled with BrdU as described in (C). At least 300 cells were counted for BrdU staining. The percentage of BrdU-positive cells was measured. Data shown are from a typical experiment performed in triplicates. (E) Inhibition of microfocus formation. NIH3T3 cells were co-transfected with HER2/neu and increasing amounts of p27. After 3 weeks, the numbers of microfoci for each transfectant were visualized using crystal violet staining. The percentage of microfoci from HER2/neu transfection was normalized to 100. The bar graph shows the relative percentage of microfoci from each transfection a pUHD10-3 hygromycin vector . We were able to identify at least six clones (6/ 10), and one representative clone can express p27 in the absence of tet as detected by immunoblotting with anti-FLAG antibody ( Figure 2B ). The overexpression status of HER2/neu was not aected in the presence or absence of tet in these clones. These results indicate that the tet-regulated system can be used to evaluate the inhibitory eect of controlled gene expression of p27 in HER2/neu-overexpressing cells. To assess the p27-mediated anti-proliferative eects, we measured and compared the antimitogenic activity of p27-expressing cell lines and parental control cell lines by performing a CDK2 kinase assay and FACS analysis. The p27-expressing cells (NIH3T3/HER2/tTA-p27 in the absence of tet) exhibited a reduced CDK2-associated kinase activity as well as an increased G1 population as compared with their controls (NIH3T3/ HER2/tTA-p27 in the presence of tet), whereas parental controls (NIH3T3/HER2/tTA) exhibited no dierence in CDK2 activity and cell cycle progression in the presence or absence of tet ( Figure 2C,D) . Similarly, BrdU incorporation ( Figure 3A ,B), and growth rate as determined by 3-(4-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay (MTT assay) (Laronga et al., 2000) ( Figure 3C ) were Figure 2 A tet-o inducible p27 expression system in NIH3T3/HER2 cells. (A) Activity of the tetO/HCMVIE promoter in NIH3T3/HER2/tTA cells which stably express tTA. NIH3T3/HER2 cells were transfected with pUHD15-1 (neo) tTA. Eight independent clones of NIH3T3/HER2 cells that express tTA were cloned and transiently transfected with pUHC13-3 (tet O/HCMV IE-Luciferase Fire¯y) in the presence (2 mg/ml, +) or absence (7) of tet. Folds of luciferase activity induction from each clone are shown. Clones that can activate luciferase activity in the absence of tet compared with the presence of tet (2 mg/ml) were used for further transfection with p27 gene cloned in pUHD10-3 hygromycin vector. (B) Con®rmed expression of p27 in the tet-o inducible system. pUHD10-3 hygromycin carries a multiple cloning site under the control of tetO/HCMVIE promoter. c-DNA of Flag-tagged p27 was cloned into pUHD10-3 hygromycin vector, and the construct was transfected into NIH3T3/HER2/tTA cells. Transfectants were selected in 600 ug/ml G-418, 300 ug/ml of hygromycin, and 2 mg/ml of tet. To examine the expression of these constructs, the culture medium was switched to medium alone or medium containing 2 mg/ml of tet. NIH3T3/HER2/tTA cells and clones that expressed Flag-p27 in the absence of tet were probed by immunoblotting with anti-FLAG antibody. The HER2/neu levels were immunoblotted with anti-HER2 antibody. The level of actin was used as an equal loading control. (C) Inhibition of CDK2-associated Histone H1 (HH1) kinase activity. 10-1 cells (NIH3T3/HER2 cells), NIH3T3/HER2/tTA cells, and NIH3T3/HER2/tTAp27 cells were used for CDK2-associated Histone H1 kinase assay. Cells were cultured in medium alone (7) or medium containing 2 mg/ml of tet (+). (D) Induction of G1 arrest by tet-regulated p27 in HER2/neu-overexpressing cells. NIH3T3/HER2/tTA cells and NIH3T3/HER2/tTA-p27 cells were used for FACS analysis. Cells were cultured in the presence (+) or absence (7) of tet for 16 ± 20 h. Cells were collected in a sorter and subjected to¯ow cytometry to analyse the cell cycle distribution according to DNA content. The percentage distribution in dierent cell cycle compartments is indicated in the stacked column graph Oncogene Tumor suppression activity of p27 and HER2/neu oncogene H-Y Yang et al dramatically reduced in the p27-expressing cells (NIH3T3/HER2/tTA-p27 in the absence of tet). Thus, our data strongly suggest that overexpression of p27 can function as a growth inhibitor in HER2/neuoverexpressing cells.
Tet-regulated p27 reverses the transformation phenotypes of HER2/neu-overexpressing cells
The HER2/neu oncogene can induce transformation by causing microfocus formation and enabling cells to grow in soft agar. To determine whether p27 expression in HER2/neu-overexpressing cells can inhibit HER2/neu-induced cell transformation, we measured the number of microfoci formed and the number of colonies formed in soft agar for transformation phenotype. Overexpression of p27 induced through tet regulation reduced the number of HER2/ neu-induced microfoci more than 95% ( Figure 4A ) as compared with controls. NIH3T3 cells served as negative controls. In a soft agar colony assay to determine anchorage-independent growth, tet-regulated overexpression of p27 reduced the HER2/neuinduced formation of colonies by a mean of 80% ( Figure 4B,C) . These results demonstrated that overexpression of p27 through tet regulation can suppress in vitro transformation phenotype of HER2/neu-overexpressing cells. 
Dox-regulated p27 suppresses tumor growth of HER2/ neu-overexpressing cells in nude mice
As p27 blocked HER2/neu-induced cell transformation, we assessed its eect on HER2/neu-mediated tumorigenicity in vivo. To verify the possible anti-tumor activity of p27, we performed a tumorigenicity assay in immunode®cient strains of mice by doxycycline (dox, a derivative of tetracycline) induction. NIH3T3/HER2/ tTA-p27 cells were treated with tet or without tet for 18 h and injected subcutaneously into the¯anks of nude mice, and tumor formation was assayed. HER2/ neu-mediated tumorigenesis was dramatically lower in p27-expressing cells (NIH3T3/HER2/tTA-p27 in the absence of dox) than in control cells (NIH3T3/HER2/ tTA-p27 in the presence of dox) ( Figure 5A ). Same results were obtained when two other independent clones were used for tumorigenesis assay (data not shown). Tumor tissues from the sites of implantation were assessed for p27 levels by immunoblotting. As expected, transduced Flag-p27 are absent in tumors of NIH3T3/HER2/tTA-injected control mice regardless the presence or absence of doxycycline in drinking water. p27 was also not detected in tumors of NIH3T3/ HER2/tTA-p27-injected mice given drinking water containing doxycycline, whereas transduced Flag-p27 was detected in the small tumors of NIH3T3/HER2/ tTA-p27-injected mice given drinking water without doxycycline ( Figure 5B ), suggesting that the expression of p27 is directly involved in inhibiting tumor growth. These results demonstrate that overexpression of p27 is sucient to abolish tumorigenicity in cells transformed by HER2/neu.
Discussion
Oncogenic activation of HER2/neu promotes the induction and progression of human cancers, including breast and ovarian cancers. We previously identi®ed Figure 4 Tet-regulated expression of p27 inhibits the transformation phenotype of HER2/neu-overexpressing cells. (A) Microfocusformation assay. NIH3T3/HER2/tTA cells and NIH3T3/HER2/tTA-p27 cells were subjected to microfoci formation assay in the presence (+) or absence (7) of tet. (B) Soft-agar colony formation assay. NIH3T3/HER2/tTA cells and NIH3T3/HER2/tTA-p27 cells were measured for anchorage-independent growth in soft agar in the presence (+) or absence (7) of tet. (C) Relative per cent of colony formation in soft agar as shown in (B). Colonies were counted in NIH3T3/HER2/tTA-p27 cells in the presence or absence of tet. The number of colonies from each cell treated with tet was set as 100%. The relative per cent of colony formation from cells cultured in the absence of tet is shown p27 as a downstream target of HER2/neu oncogenic signals and found that p27 abundance was decreased in HER2/neu-overexpressing cells . Clinical studies of breast cancer tumor samples also indicated that overexpression of HER2/neu correlates with low levels of p27 (Newman et al., 2001) , suggesting a critical role of p27 in proliferative and transforming signals of oncogenic HER2/neu. The lowlevel expression of p27 caused by HER2/neu is mediated through enhanced ubiquitin-mediated degradation of p27 via Grb2/MAPK pathway . Here, we showed that overexpression of p27 abolished the growth of HER2/neu-transformed cells in immunode®cient mice, thus showing the eectiveness of p27 as a potential therapeutic agent for HER2/neuassociated cancers.
As a downstream target of the HER2/neu oncogenic signaling pathway in cancer cells, p27 represents a logical target for intervention using gene therapy. Mitogenic signals of HER2/neu can elevate CDK2 activity, induced cell transformation, and increase tumorigenesis while decreasing the expression of p27. Here, we showed that p27 can inhibit HER2/neuactivated CDK2 activity, cell transformation, and tumorigenesis, suggesting that in addition to its role as a cell cycle inhibitor, p27 acts as a transformation inhibitor and as a tumor suppressor. Cell cycle studies of HER2/neu-mediated transformation showed that cyclin D1 antisense inhibited HER2/neu-mediated transformation in a dose-dependent manner and suppressed the growth of HER2/neu-transformed mammary cells in nude mice, suggesting that cyclin D1 plays a critical role in proliferative and transformation signals downstream of oncogenic HER2/neu . This observation may explain how p27 inhibits cell transformation: p27, which acts as an inhibitor of cyclin D1-associated kinase (Lee et al., 1995; Polyak et al., 1994) , may also inhibits HER2/neumediated transformation by inhibiting cyclin D1 activity. Our studies show for the ®rst time that p27 acts as an anti-transformation eector inhibiting HER2/neu-mediated cell transformation.
HER2/neu overexpression has been found with high frequency in many kinds of carcinoma, suggesting that HER2/neu overexpression plays a critical role in the development of malignancy. Therefore, the HER2/neu receptor is a target for the development of therapeutic agents for HER2/neu-overexpressing human cancers. Many strategies are focused on targeting the receptor including employing antibody (Herceptin) (Pegram et al., 1999; Baselga et al., 1998) . Recently, the recombinant humanized anti-HER2/neu monoclonal antibody (trastuzumab) has been used in human clinical trials for treatment of women with metastatic breast cancer overexpressing HER2/neu. It was found that HER2/neu monoclonal antibody has an eect in growth inhibition by upregulating p27 in HER2/neuoverexpressing cancer cells (Le et al., 2000) , suggesting that modulating p27 may mediate the therapeutic eect of the monoclonal antibody. Our tumor model study suggests that p27 gene therapy may be an alternative strategy for the treatment of HER2/neu-associated tumors.
A high level of expression and controlable gene delivery are two important factors to accomplish eective gene therapy. Here, we used the human p27 gene, controlled by the tetO/promoter, to evaluate the applicability of controled gene expression in HER2/ neu-associated cancer for gene therapy. Our data showed that p27 expression by the transduced HER2/ neu-overexpressing cells could inhibit tumor growth in nude mice. Future direction is to show better clinical relevance in terms of growth reversal of established tumor. Slow tumor growing and HER2-overexpressing cancer cells, such as MDA-MB-361, can be employed for re-expressing p27 by tet-regulation in an xenograft model. Tumor will be established in the presence of dox, and the reversal of tumor growth by re-expressing p27 through removal of dox will be evaluated. NIH3T3/HER2/tTA-p27 cells may not be used in such experiments due to fast tumor growth rate. These studies will further demonstrate the in vivo feasibility of the tet-regulated system in gene therapy for HER2/neuoverexpressing cells and provide perspectives on future gene therapy using dierent adenovirus or retroviral expression vectors to achieve optimal p27 expression by tet-regulated system. In conclusion, our studies show that overexpression of p27 can inhibit HER2/neu-mediated tumor growth, suggesting that p27 gene transduction is a useful new strategy of anticancer gene therapy for HER2/neuassociated cancers.
Materials and methods
Cell culture
R1B/L17, NIH3T3, and NIH3T3/HER2 cells were cultured in DMEM media containing 10% fetal bovine serum. A DEAE-dextran method was used to transiently transfect R1B/L17 cells (more than 70% of transfection eciency) as described previously (Lee et al., 1995) . NIH3T3/HER2/tTA cell line was generated by transfecting pUHD15-1 (neo) (Gossen and Bujard, 1992) into NIH3T3/HER2 cells using Fugene 6 transfection reagent (Boehringer Mannheim) following the manufacturer's guidelines. Two days after transfection, cells were selected in 600 mg/ml G418 media for 2 ± 3 weeks. Positive clones were selected and assayed by transient transfection of pUHC13-3 (tetO/HCMVIE-luciferase) (Gossen and Bujard, 1992) . Luciferase activity was measured as described previously (Wen et al., 2000) . Flag-tagged p27 cloned in pUHD10-3 hygromycin vector was introduced into NIH3T3/HER2/tTA cells by Fugene 6 reagent and 300 ug/ ml Hygromycine B with 2 mg/ml tet was used to select for positive clones over 2 ± 3 weeks. Positive NIH3T3/HER2/ tTA-p27 clones were detected by Western blot analysis using anti-FLAG (M2) antibody (Sigma).
Western blot
Cells were lysed in the buer previously described and the protein amounts were quanti®ed using the Bio-Rad kit. For mouse tumor samples, tissues were homogenized in a RIPA buer containing 16 PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS and proteinase inhibitors using a tissue homogenizer (PowerGen 125, Fisher) . Equal amounts of protein were loaded onto 12 or 8% SDS polyacrylamide gels. Antibodies used in the study were anti-¯ag (M2) (Sigma), anti-c-neu (Oncogene), and polyclonal anti-actin antibody (Sigma).
The CDK2-associated Histone H1 kinase assay NIH3T3/HER2, NIH3T3/HER2/tTA and NIH3T3/HER2/ tTA-p27 cells were cultured in the media with or without 2 mg/ml tet for 16 ± 20 h before harvesting. For transfected cells, cells were harvested 48 h post-transfection. Cells were lysed and 1 mg of total cell lysate was immunoprecipitated with polyclonal anti-cdk2 antibody (Pharmingen). The immunoprecipitates were assayed for Histone H1 kinase activity as described previously .
MTT assay
The MTT assay was done as described (Laronga et al., 2000) . Brie¯y, cells were seeded at 3000 cells/well in a 96-well plate in the presence or absence of the 2 mg/ml tet for each cell line. Each sample has four replicates. Cell growth was measured for 7 days. Each day cells were incubated with 50 ul of 0.2% MTT for 2 h at 378C in the 5% CO 2 incubator. Following MTT incubation, cells were lysed in 200 ul of 100% DMSO and the absorbance at 570 nm was obtained using the 96-well plate reader (Dynex Technologies).
5-Bromo-2-deoxy-Uridine (BrdU) incorporation assay
For transient transfection, pCMV5-p27, pcDNA3-HER2, pCMV5, or a combination of pCMV5-p27 and pcDNA3-HER2 was transiently co-transfected into R1b/L17 cells. Cells were trypsinized and plated onto 4-well chamber slides 24 h after transfection. BrdU incorporation was performed 48 h after transfection using a BrdU labeling and detection kit (Boehringer Mannheim) following manufacturer's guidelines. For stable lines, NIH3T3/HER2/tTA and NIH3T3/ HER2/tTA-p27 were cultured in the media with or without tet for 16 ± 20 h prior to performing BrdU incorporation assay. For all staining, cells were incubated with 0.1 mg/ml of 4,6-diamidino-2-phenylindole (DAPI) (Sigma) to stain the nuclei. Immuno¯uorescence was detected using Axioplan 2 uorescent microscope (Zeiss).
FACS-propidium iodine staining
Cells were cultured in DMEM complete media with or without 2 mg/ml tet for 16 ± 20 h prior to propidium iodine staining. Cells were trypsinized and washed twice with PBS, then collected in 15 ml conical tubes. Following ®xation of cells in cold 70% ethanol at 48C for 1 h, cells were spined down and incubated at 378C for 30 min in the buer containing 50 mg/ml propidium iodine, 5 mM MgCl 2 , 10 mM Tris-Cl pH 7, 25 mg/ml RNaseA. Before FACS analysis, cells were continuously incubated overnight at 48C.
Soft agar colony formation assay
The soft agar colony formation assay was performed as described previously (Laronga et al., 2000) . In brief, 2000 cells/well mixed in a 0.35% agarose/complete media were seeded onto 0.7% agarose/complete media bottom layer in the presence or absence of 2 mg/ml tet in a 24-well plate. A drop of media containing 2 mg/ml tet was added every 3 days for tet present group. Four weeks later, cells were stained with p-iodonitrotetrazolium violet (Sigma) for 16 h before being photographed.
Microfocus formation assay
Microfocus forming assay system was performed as previously described (Reardon and Hung, 1993) . Brie¯y, 400 cells of NIH3T3/HER2/tTA or NIH3T3/HER2/tTA-p27 cells were mixed with NIH3T3 cells (6.5610 6 /10 cm plate) and cultured in the media with or without 2 mg/ml tet. Medium was changed every 2 days over the 3-week period of focus formation. At the end of 3 weeks, cell monolayers were stained in crystal violet solution (0.5% crystal violet, 20% methanol) and then destained in running tap water for 30 ± 60 min. Foci were then counted and photographed.
Tumor growth in nude mice
Female 4 ± 5-week-old nude mice (Charles River Laboratories, Wilmington, MA, USA) were maintained in the animal facility at the University of Texas MD Anderson Cancer Center. Mice were divided into two experimental groups, four for each. NIH3T3/HER2/tTA-p27 cells (1610 6 cells in 0.2 ml PBS per injection with 2 mg/ml tet for one group, and without tet for other) were injected subcutaneously into the¯anks of mice, and each mouse was inoculated with cells at two sites. After cell inoculation, animals were fed with drinking water containing 5% sucrose in the presence or absence of 200 mg/ml doxycycline (Sigma) (Kistner et al., 1996) . Drinking water was changed every other day for a 2-week period of tumor formation. Tumor volumes were measured and recorded three times a week from day 5 of cell inoculation. At the end of 2 weeks, the mice were sacri®ced and the tumors were removed for detection of p27 gene expression.
